Audit: QRS - Transcutaneous Electrical Nerve Stimulation for Health & Longevity

Audit conducted on 09/08/2026 22:01 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol parameter, time-to-effect value, tiered benefit and risk, gate item, biomarker target and qualitative marker traces to a specific ER passage (ER lines 376–380, 424, 342–352, 446–466).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Speculative-tier items in Benefits and Risks carry the ER’s own speculative framing; no ER hedge is dropped in favour of a firm statement.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	ER absolute contraindications appear in the Contraindications gate, ER “Caution” entries in the Key Interactions gate; no tier or severity migration.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates derive solely from ER Key Interactions & Contraindications; risks from Potential Risks & Side Effects; benefits from Expected Benefits. No modifier-factor content is repurposed.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names, or device brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No institutions, investigators, or organisations are named in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Protocol panel and monitoring table are data-driven; At-A-Glance frames a low-cost, low-downside option without overselling.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively; no imperatives directed at a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs; gates and monitoring ranges are presented as evidence, and the footer disclaimer is intact.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “advised”, or “should” constructions appear.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the rendered content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are the ER’s own necessary ones (hyperalgesia, spasticity, N-methyl-D-aspartate); no gratuitous jargon added.
2.8	Information is presented in a concise and very compact manner	🟢	All list items are single short clauses; no item carries an explanatory tail.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing centres on dose adequacy, tolerance management, and preserving activity — decisions only a proactive user makes.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Two-hours-daily modulated protocol, per-session re-titration, and electrode rotation are presented without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Detail level (pulse widths, frequency ranges, biomarker panel) assumes an engaged reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance makes the dose-dependence explicit, which is the distinguishing consideration for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The term “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terms used throughout (“analgesic”, “contact dermatitis”, “spasticity”); the plain wording in At-A-Glance is required by item 7.4 and mirrors the ER Conclusion.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings verified verbatim (lines 445, 488, 536, 569, 581, 605, 636, 640–642, 738) and all four tier labels present in both Benefits and Risks.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	60 named spans present and coherent: header (4), at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits (4), risks (4), stop_items, caution_items, marker_1–6 (name/target/why), monitoring_cadence, qualitative_item_1–8.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" template spans, the stylesheet link, and the CSS block are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped to the QRS is empty; all four benefit tiers, all four risk tiers, both gates, the biomarker table and the qualitative list carry content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	All three protocol labels are the ER’s bold labels verbatim (ER lines 376, 378, 380); biomarker row labels match the ER table column 1 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol and marker labels are exact; time-to-effect labels are minimal descriptors drawn from ER prose (ER line 424), and gate-item shortening is the concision explicitly mandated by items 8.4/8.5 and 9.4/9.5.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; tiering is conveyed by bold labels and the CSS palette.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to single-line entries: benefit and risk tiers are collapsed into semicolon-separated clauses, gate items carry no rationale, and the biomarker “Why” cells are one clause each.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; it is the first element following the doctype and precedes the template comment at line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the caption text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are repeated in a visible element other than the date and model required by items 6.3 and 6.4.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4 states the correct source ER filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the guideline version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0809-2105, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename on disk exactly.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Transcutaneous Electrical Nerve Stimulation for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417 carries the canonical topic with & encoding.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/09/2026”, the correct MM/DD/YYYY rendering of 2026-0809.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” line is correctly omitted.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Lines 434–437 condense ER lines 486–488, retaining the execution-critical point that benefit depends on a strong but comfortable, re-titrated current.
7.2	[at_a_glance] is no longer than 60 words	🟢	54 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Low cost and drug-free (ER 486), pain lower during and briefly after (ER 486), postoperative analgesic sparing (ER 486), smaller gains in chronic pain with dose dependence (ER 486), small downside (ER 488).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “painkilling medication”, “mild electrical pulses through the skin”, and “longer-lasting pain” replace clinical register.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author, year, or sample size is named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates or confidence intervals appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items map to the ER “Absolute contraindication” bullets at ER lines 344–348.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER absolute contraindications are represented, none omitted and none invented.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 572–576: five discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dash-introduced tails; the ER’s rationale clauses (bradycardia, laryngospasm, clot mobilisation) are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Retained: “electrodes both sides or across the chest”, “outside labour, especially first trimester”, “at the site” for deep vein thrombosis.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its contraindication bullets.
8.7	If no [stop_items] are present the section is left empty	N/A	Five stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All twelve items map to ER lines 326–340 and the four “Caution” entries at ER lines 349–352.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets plus the four ER caution populations are present; no overlap with the five absolute contraindications in the stop gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 584–595: twelve discrete <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “— caution, reduced effect” / “— additive, low risk” tails and all mitigating-action prose are stripped; no dash appears in any item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drugs kept in trimmed form for every applicable item (morphine, oxycodone; naltrexone; ibuprofen; capsaicin; curcumin; electroacupuncture) and the qualifiers “seizure within 12 months”, “failed monofilament test”, “moderate to severe dementia” are retained.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its interaction bullets.
9.7	If no [caution_items] are present the section is left empty	N/A	Twelve caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	The three cells correspond to the first three bullets of the ER Therapeutic Protocol section (ER lines 376, 378, 380).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The conventional high-frequency, acupuncture-like low-frequency, and modulated-frequency protocols are the ER’s three executable dosing regimens; the remaining ER bullets are contextual modifiers rather than protocols.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more distinct actionable protocols, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content: labels verbatim, values give frequency and duration, subs give pulse width and the intensity endpoint.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Within-session onset, post-session carry-over, and cumulative benefit are the three timescales the ER identifies (ER lines 386, 424).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered from the high-tier within-session analgesia, to its carry-over, to the smaller and less certain cumulative effect.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER describes three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content: “Within minutes”/”Maximal by 20 to 30 minutes”, “30 minutes to several hours”/”Longer at low frequency”, “2 to 4 weeks”/”over ten or more sessions”.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect information at ER line 424, so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve entries map one-to-one to the twelve ER benefit headings across the four tiers (ER lines 148–224).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated (lines 538, 544, 551, 557).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a noun phrase; no standardized mean differences, confidence intervals, or numbers needed to treat are carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry ER content, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven entries map one-to-one to the eleven ER risk headings across the four tiers (ER lines 246–310).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present and populated (lines 607, 613, 619, 625).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a noun phrase; the ER’s frequencies (under 5%, 47.1%, numbers needed to harm) and mechanisms are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry ER content, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER Monitoring Protocol & Defining Success biomarker table (ER lines 446–453).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All six ER biomarkers present with matching targets: hs-CRP < 1.0 mg/L, IL-6 < 1.8 pg/mL, HbA1c 4.8–5.4%, vitamin B12 500–900 pg/mL, 25-hydroxyvitamin D 40–60 ng/mL, red blood cell magnesium 5.0–6.5 mg/dL.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 728–732 condense ER line 455: first-session response, skin after every use, review at 2 and 4 weeks, tolerance at 6 to 8 weeks, reassessment every 3 to 6 months, blood panel at 3 months then 6 to 12 monthly.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	The eight items map to the ER’s qualitative marker bullets (ER lines 459–466).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All eight ER qualitative markers are present, in the ER’s own order, with none omitted or added.

Issues 09/08/2026 22:01

Pass rate 100.00%. No issues found.

Issues 09/08/2026 21:54

1. 1.3 — Intensity qualifier softened: [action_1_sub] (line 456) states “comfortable tingling, no twitch”, dropping the “strong but” from the ER’s “strong but comfortable tingling” (ER line 376), which weakens the intensity requirement the ER identifies as the dominant determinant of effect.
2. 1.1 — Pooled analysis pluralised: [marker_2_why] (line 668) says “Most consistently reduced marker in pooled analyses”, while the ER attributes interleukin-6 reduction to a single pooled analysis of five trials (ER lines 449, 208).
3. 9.5 — Dementia severity class dropped: The caution item “Cannot operate device or report sensation (dementia)” (line 595) omits the ER’s severity qualifier “moderate to severe dementia” (ER line 352).

Fixes 09/08/2026 21:54

1. 1.3 — Intensity qualifier restored: [action_1_sub] changed from “comfortable tingling, no twitch” to “strong but comfortable tingling, no twitch”, matching the ER’s protocol wording.
2. 1.1 — Pooled analysis singular: [marker_2_why] changed from “in pooled analyses” to “in the pooled analysis”, matching the single pooled analysis cited in the ER.
3. 9.5 — Dementia severity class restored: The caution item now reads “Cannot operate device or report sensation (moderate to severe dementia)”, preserving the ER’s severity qualifier.

Issues 09/08/2026 21:45

1. 4.5 — Sheet overflows one A4 page: Visible text totals ~5,366 characters against a corpus median of ~3,413, with the Protocol action cells (lines 447-488, ~666 characters) at the 99th percentile and Time-to-effect (~398), Key Interactions (~692), Qualitative Assessment (~549), Benefits (~551) and Risks (~536) all at or above the 90th percentile; a source-level layout estimate puts the stack from the header through the 12-item Key Interactions gate at the full printable A4 height before Risks, Monitoring, and Qualitative Assessment are laid out.

Fixes 09/08/2026 21:45

1. 4.5 — Protocol and Time-to-effect cells condensed: Trimmed the three action_#_sub cells (e.g. “Pulse width 50–200 microseconds; strong, comfortable tingling without muscle contraction; electrodes bracket the painful area.” → “Pulse width 50–200 microseconds; comfortable tingling, no twitch.”) and the three time_#_sub cells (e.g. “Where it occurs, develops over ten or more sessions; a first 30-minute session predicts the one-month outcome.” → “Where it occurs, over ten or more sessions.”), cutting the Time-to-effect region from the 97th to the 81st percentile of the published QRS corpus.
2. 4.5 — Key Interactions gate shortened: Reduced all twelve caution_items to single-line entries by trimming the parenthetical example lists rather than dropping them (e.g. “Other neuromodulation (electroacupuncture, spinal cord stimulation)” → “Other neuromodulation (electroacupuncture)”; “Complete sensory loss (failed 10 gram monofilament test)” → “Complete sensory loss (failed monofilament test)”), removing roughly eight wrapped lines from the tallest gate column.
3. 4.5 — Benefits and Risks tiers tightened: Condensed all eight tier lines to the bare key fact (e.g. risks_speculative “Blunted protective pain signalling during exercise; effects on uterine activity and the fetus in pregnancy; long-term opioid system downregulation” → “Blunted protective pain signalling in exercise; uterine and fetal effects in pregnancy; opioid downregulation”), moving Benefits from the 91st to the 84th and Risks from the 93rd to the 87th percentile.
4. 4.5 — Contraindications, cadence, and Qualitative Assessment trimmed: Shortened the two wrapping stop_items, compressed monitoring_cadence from 230 to 211 characters, and reduced the eight qualitative entries to single lines each, keeping every item and every decision-gate qualifier while bringing total visible text from ~5,366 to ~4,509 characters.

Issues 09/08/2026 21:36

1. 4.5 — Content exceeds one A4 page: The sheet carries 879 words / ~6,451 visible characters, while the print stylesheet (9.5pt body, 1.42 line-height, 186mm content width after the 12mm .sheet padding) leaves room for only ~6,300 characters even before headings, card padding, table-row padding, the 24pt title, the 16px At-A-Glance block, and the half-width gate grid are counted; the 12-item Key Interactions gate (lines 599-618), the six Monitoring “Why” cells (lines 680-753), the three protocol .sub cells (lines 456-487), and the cadence sentence (lines 760-765) each carry near-full ER sentences rather than condensed ones.

Fixes 09/08/2026 21:36

1. 4.5 — At-A-Glance tightened: Condensed [at_a_glance] from 58 to 54 words, dropping the redundant “with varied settings” clause and shortening “Pain is lower while the current runs and briefly afterwards” to “Pain falls while the current runs and briefly after”.
2. 4.5 — Protocol sub-cells condensed: Trimmed the three [action_#_sub] cells from two full sentences to one, removing the mechanistic tails (“within the same spinal segment”, “preferred for deep or diffuse pain”, “Sweeping delays the tolerance fixed parameters induce”), saving roughly two wrapped lines per cell.
3. 4.5 — Time-to-effect sub-cells shortened: Reduced [time_2_sub] to “Longer after low-frequency stimulation; shortens as tolerance develops” and [time_3_sub] to “a first 30-minute session predicts the one-month outcome”.
4. 4.5 — Benefits card compressed: Merged the three low-tier pain entries into “Reduced chronic low back, neuropathic, and menstrual pain” and shortened the high, medium, and speculative entries, cutting the card from eight to six wrapped lines.
5. 4.5 — Risks card compressed: Removed the redundant descriptors (“redness”, “or vasovagal response during stimulation”, “from excessive current density or degraded electrodes”, “progressive or”), cutting the card from nine to six wrapped lines.
6. 4.5 — Contraindications shortened: Stripped the repeated “Placement over/across” prefixes and trimmed the pregnancy and skin/thrombosis entries, taking the stop gate from eleven to eight wrapped lines while keeping all five items and their qualifiers.
7. 4.5 — Key Interactions trimmed: Shortened all twelve interaction items and their example-drug parentheticals (e.g., “morphine, oxycodone, tramadol, buprenorphine” to “morphine, oxycodone, tramadol”), taking the caution gate from about twenty-four to nineteen wrapped lines without dropping any item.
8. 4.5 — Monitoring cells condensed: Reduced all six [marker_#_why] cells to a single wrapped line each and shortened [monitoring_cadence] from about 253 to 200 characters, halving the height of the Monitoring card.
9. 4.5 — Qualitative items shortened: Trimmed items 1, 3, and 6 so every entry fits one wrapped line, dropping the trailing “before and during application”, “available”, and “for long-term independence” clauses. Overall visible text fell from 879 words / 6,451 characters to 732 words / 5,356 characters.

Issues 09/08/2026 21:25

1. 2.7 — Latinate jargon in Contraindications: Line 583 states the contraindication as “Transcerebral and transocular placement”, two specialist terms a non-specialist cannot decode, where the ER itself supplies the plain equivalent at line 346 (“Electrodes across the head or over the eyes”).

Fixes 09/08/2026 21:25

1. 2.7 — Plain wording for head/eye contraindication: Replaced the Contraindications item “Transcerebral and transocular placement” with the ER’s own plain equivalent, “Placement across the head or over the eyes”.

Issues 09/08/2026 21:15

1. 4.5 — One-page budget exceeded: The sheet carries 7,210 characters of visible body text, roughly two to three A4 pages at the template’s 9.5pt card type; the action subs (QRS 456–460, 471–475, 486–490), five Monitoring “Why” cells (QRS 694–697, 736–739, 750–754, 765–768), the cadence paragraph (QRS 775–780), the qualitative items (QRS 789–830) and the long parenthetical drug lists in [caution_items] (QRS 609–620) are carried at near-ER length instead of being condensed to the per-section budget.

Fixes 09/08/2026 21:15

1. 4.5 — Over-budget regions condensed: Visible body text was cut from 7,210 to 6,458 characters by tightening the three action subs, the three time subs, the six Monitoring “Why” cells, the cadence paragraph, four qualitative items, the parenthetical drug lists in [caution_items], and three [stop_items], while keeping all 5 contraindications, all 12 key interactions, all 6 biomarkers and all 8 qualitative markers intact.